Latest News & Blog

Inspiring & original thinking. And, the latest news about us.

THINKING

Welcome to Well Filtered™

A blog series dedicated to unearthing the ideas, perspectives, and innovations that matter most in kidney health.

Is there real value in value-based care? 02.08.22

A SPECIAL, NEW YEAR INVESTIGATIVE BLOG: Making Sense of Population Health, Precision Medicine & Value-Based Care with Mount Sinai’s Dr. Arshad Rahim 01.06.22

An “Inside Look” at Precision Medicine, Cardiovascular & Kidney Disease: We Get It Straight from Bayer’s, Dr. Amit Sharma 10.26.21

A “How To” Playbook for Disrupting Kidney Care: Our Live Chat with the National Kidney Foundation’s Chief Medical Officer 09.20.21

Are Kidney-Focused Clinical Studies Finally Hitting Their Groove? The Trials to Watch & Why 08.10.21

3 Ways We’re Translating Lessons Learned in Cancer to Help Fix the Kidney Care Model 7.27.21

6 Tipping Point Innovations in Kidney Care: A Leading Expert Shares His POV 6.28.21

Why a Shift in Thinking from Kidney Disease to Kidney Health is Mission-Critical. A Candid Conversation with NKF’S Former President & Board Member, Holly Kramer. 6.02.21

NEWS

Renalytix Appoints Joseph Hutson Vice President of Global Quality and Regulatory 07.22.21
Hutson to Build on Renalytix Quality and Regulatory Strategy for KidneyIntelX Global Commercialization NEW YORK and SALT LAKE CITY, July 22, 2021 (GLOBE NEWSWIRE) -- Renalytix Plc (NASDAQ: RNLX) (LSE: RENX) today announced the appointment of Joseph Hutson as its Vice President of Quality and

Read More
KidneyIntelX™ Enables Monitoring of SGLT2 Inhibitor Therapy Response and Corresponding Risk Reduction Over Time 06.28.21
Study Results lay foundation for KidneyIntelX repeat testing, reimbursement, and pharma collaborations NEW YORK, June 28, 2021 (GLOBE NEWSWIRE) -- Renalytix plc (LSE: RENX) (NASDAQ: RNLX) announces new data demonstrating KidneyIntelX™ can be effective at monitoring therapeutic response and

Read More
Renalytix Reports Financial Results for Third Quarter of Fiscal Year 2021 06.15.21
NEW YORK, June 15, 2021 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX) (“Renalytix” or the “Company”) today reported financial results for the quarter and nine months ended March 31, 2021. Recent Highlights Partnership announced with University of Utah health system to improve

Read More
Renalytix to Report Financial Results for Fiscal Third Quarter 2021 and Provide Corporate Update 06.10.21
Announces Change of Auditor to Ernst & Young LLP NEW YORK, June 10, 2021 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX) today announced the Company will release fiscal third quarter 2021 financial results on Tuesday, June 15, 2021, before market open.

Read More
Leadership Additions Announced to Support Expanding US Government and Healthcare Provider KidneyIntelX Deployment 06.07.21
Enabling expertise in sales, population health and value-driven care models NEW YORK and SALT LAKE CITY, June 07, 2021 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX) today announced a series of key hires to drive its commercialization strategy in the United States market in light

Read More
Utility Study Indicates KidneyIntelX Risk Assessment can Address Treatment Ambiguity in Primary Care 06.03.21
Clinicians affirm need for accurate early-stage diabetic kidney disease risk assessment to improve patient outcomes and reduce healthcare costs NEW YORK, June 03, 2021 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX) today announced results from a new utility study.

Read More
Atrium Health, Wake Forest Baptist Health, Wake Forest School of Medicine and Renalytix Partner to Advance Kidney Health 05.19.21
Partnership marks a long-term commitment to reducing impact of kidney disease in large populations via integration of earlier risk assessment paired with comprehensive disease management NEW YORK and CHARLOTTE, N.C. and WINSTON-SALEM, N.C., May 19, 2021 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE:

Read More
U.S. General Services Administration Grants 10-Year Governmentwide Contract for RenalytixAI KidneyIntelX Testing 04.22.21
KidneyIntelX Testing Services Available to 140 U.S. Government Departments, Agencies and Affiliates Around the World NEW YORK, April 22, 2021 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX) today announced that the United States Government has granted the company a 10-year

Read More
KidneyIntelX Demonstrates Performance and Informs Treatment Decisions in Multinational CANagliflozin CardioVAScular Assessment Study (CANVAS) 04.20.21
Data from 1,325 CANVAS Participants with Baseline DKD Scored with KidneyIntelX Presented at International Society of Nephrology World Congress of Nephrology 2021 NEW YORK, April 20, 2021 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX) announces the findings of a new study in which

Read More
RenalytixAI and Joslin Diabetes Center Build on Proprietary Kidney Biomarker Portfolio for KidneyIntelX Platform 04.14.21
Agreement provides RenalytixAI with exclusive option to access intellectual property surrounding a comprehensive panel of novel biomarkers in kidney disease NEW YORK, April 14, 2021 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX) announced today that it has entered into an exclusive

Read More